Clinical trial registry record

Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Terminated.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated December 19, 2020.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT01624636
Last registry update
December 19, 2020
Status
Terminated
Phase
Phase 2
Sponsor
Novartis Pharmaceuticals
Enrollment
1
Countries
United States
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
Evidence population
Human clinical study registration
Participants
1
Population
ALL · 55 Years to 90 Years
Duration
2012-12-01 to 2013-05-01
Intervention
Placebo; LFG316
Comparator
Placebo
Outcomes measured
Number of anti-vascular endothelial growth factor (anti-VEGF) retreatment vs time — Day 1 to Day 113 (starting from the…; Number and percentage of patients with adverse events. — Day 1 to Day 113 (starting from the day of dosing until the en…; Effect of LFG316 on visual acuity — Day 1 to Day 113; Effect of LFG316 on central retinal thickness, choroidal neovascular membrane area and drusen volume. — Day 1 to Day 113; Serum concentrations of total LFG316 versus time — Days 1, 8, 15, 22, 29, 43, 57, 78, 85 and 113 for both cohorts.; Serum concentration of pharmacodynamic parameters (Weislab and C5) versus time — screening and Days 1, 8, 15, 22, 29, 4…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON